MedTrace Logo

IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

NCT03981900 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 314

Last updated 2024-10-01

Study results available
· View outcomes & findings →

Summary

Regarding Tofacitinib, newly introduced on the market, few data on drug retention and no data on the factors predictive of Tofacitinib drug survival in patients with RA are available.

Therefore, the primary objective of the DeFacTo study will be to identify the factors predictive of Tofacitinib drug survival in patients with RA.

As secondary objectives, the impact of behavioural strategies on drug survival and other clinical parameters as well as Tofacitinib effectiveness and tolerability will be studied under real-life conditions of use in French patients with RA.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Tofacitinib

5 mg BID, oral administrtaion

DRUG

Tofacitinib

tablet form 11mg once daily oral

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-04
Primary Completion
2023-02-06
Completion
2023-02-06

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03981900 on ClinicalTrials.gov